Abbott Laboratories (ABT) is back on investors’ radar after second quarter 2026 earnings showed higher year over year sales alongside lower net income and earnings per share, refocusing attention on future growth drivers.

The latest earnings release appears to have reset expectations for Abbott Laboratories, with the share price up 13.9% over 30 days and 13.1% over 90 days, even as the year to date share price return and one year total shareholder return remain in decline. This suggests improving short term momentum alongside a weaker longer term experience.

If this earnings driven move has you looking beyond Abbott Laboratories, it could be a good moment to scan other healthcare opportunities using a focused screener for 39 healthcare AI stocks

After a sharp short term rebound in Abbott Laboratories shares, the question now is whether that reset has already captured the latest earnings news or if patience for a different entry point makes more sense as the valuation is unpacked next.

Most Popular Narrative: 13.5% Undervalued

With Abbott Laboratories last closing at $103.06 against a narrative fair value of $119.13, the current setup hinges on how future growth and margins unfold under a 7.72% discount rate.

The global demographic shift toward an aging population and increasing prevalence of chronic and lifestyle-related diseases (e.g., diabetes, cardiovascular disease) is underpinning strong, recurring demand for Abbott's diagnostics, nutrition (e.g., Ensure, Glucerna), and high-growth medical device franchises, which is supporting revenue acceleration and enhanced operating leverage.

Curious what underpins that higher fair value for Abbott Laboratories? The narrative leans on faster top line expansion, rising margins, and a richer future earnings multiple. Want to see how those moving parts fit together in the model?

Result: Fair Value of $119.13 (UNDERVALUED)

However, investors in Abbott Laboratories still need to weigh pressure on diagnostics revenues from China procurement and COVID testing, along with tariff and currency headwinds that could squeeze margins.

Next Steps

With sentiment on Abbott Laboratories clearly mixed, this is the moment to review the underlying numbers yourself and decide how the risk reward trade off stacks up. To help frame that view, take a closer look at the 3 key rewards and 2 important warning signs

Looking for more investment ideas beyond Abbott Laboratories?

If you want to keep sharpening your watchlist, use the Simply Wall St Screener to uncover fresh stock ideas that fit your risk and return preferences.

• Target resilient opportunities by running the 81 resilient stocks with low risk scores, which can help anchor your portfolio through different market conditions.
• Spot potential value candidates early by scanning the screener containing 20 high quality undiscovered gems before they appear on everyone else's radar.
• Strengthen your core holdings by filtering for companies in the solid balance sheet and fundamentals stocks screener (49 results) to focus on sturdier financial profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.